Overview

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Phase:

Phase 2

Details

Lead Sponsor:

BeiGene

Treatments:

Tislelizumab